Scientific Sessions 2024
/
Genetics and Outcomes Research
/
Outstanding Research Award in Pediatric Cardiology: Prevalence, evaluation, and treatment of neurodevelopmental disorders in publicly insured children with critical congenital heart disease in the first 5 years after infant heart surgery
American Heart Association
2
0
Final ID: 4143565
Outstanding Research Award in Pediatric Cardiology: Prevalence, evaluation, and treatment of neurodevelopmental disorders in publicly insured children with critical congenital heart disease in the first 5 years after infant heart surgery
Abstract Body (Do not enter title and authors here): Background: Survivors of infant heart surgery are at greater risk for neurodevelopmental (ND) disorders. Rates of ND diagnoses (dx) and resource utilization are derived from referral centers or single-state studies, with few multi-state data on diagnosis and utilization across inpatient and outpatient settings. Methods: We characterized ND dx, medications, screening/evaluation, and non-medical therapies up to 5 years of life among children born in 2016-2020 in the Merative MarketScan Medicaid Claims database from 12 anonymized states. Surgical complexity was assessed with RACHS-2 category. Cox proportional hazards regression was used to identify risk factors for time to 1) first ND dx and 2) first ND evaluation/intervention. Results/Data: Among 3,147 patients enrolled for a mean 30.5 months, surgery was neonatal in 48%; 23% had a genetic dx; and highest RACHS-2 category was 1= 30%, 2=29%, 3=13%, 4=18%, and 5=10%. Brain imaging was performed in 13%, most commonly MRI (8%). Without adjusting for variable follow-up, the proportion with ≥1 ND dx was 41%, most commonly Communication Disorder (25%), Global Developmental Delay (15%), and Motor Disorder (19%). At latest follow-up, 85% had received ≥1 ND service and 78%, ≥1 direct intervention (ST, OT, and/or PT). Brief ND screening was completed in >58%, but few had psychological/neuropsychological (6.6%) or comprehensive developmental (8.5%) evaluation. Use of stimulants (0.5%), anti-depressants (0.1%) and antipsychotics (0.2%) were uncommon, but anticonvulsants had been used in 7.3%. Independent risk factors for earlier time to any ND dx were Black (p=0.043) or Hispanic (p=0.032) vs. White race/ethnicity, and RACHS-2 Category 4 (p=0.002) or 5 (p=0.007) vs. 1. Independent risk factors for shorter time to first ND evaluation or intervention included RACHS-2 Classes 2 (p=0.012), 4 (p<.001), and 5 (p<.001). Birth sex and genetic abnormalities were not significant predictors of ND dx or utilization. Data for center and region were not available. Conclusions: The prevalence of ND dx and utilization of ND services was high up to age 5 years in this population-based sample of publicly insured children who underwent infant heart surgery. Rates of developmental screening were comparable to those in general pediatric samples, but few children received formal ND evaluations, falling short of AHA recommendations for universal developmental evaluation.
O'meara, Daniel
( Emory University
, Atlanta
, Georgia
, United States
)
Henson, Brandi
( Boston Children's Hospital
, Jamaica Plain
, Massachusetts
, United States
)
Rollins, Caitlin
( Boston Children's Hospital
, Jamaica Plain
, Massachusetts
, United States
)
Gauvreau, Kimberlee
( Boston Children's Hospital
, Jamaica Plain
, Massachusetts
, United States
)
Berry, Jay
( Boston Children's Hospital
, Jamaica Plain
, Massachusetts
, United States
)
Hall, Matthew
( Children's Hospital Association
, Lenexa
, Kansas
, United States
)
Newburger, Jane
( Boston Children's Hospital
, Jamaica Plain
, Massachusetts
, United States
)
Author Disclosures:
Daniel O'Meara:DO NOT have relevant financial relationships
| Brandi Henson:DO NOT have relevant financial relationships
| Caitlin Rollins:DO NOT have relevant financial relationships
| Kimberlee Gauvreau:DO NOT have relevant financial relationships
| Jay Berry:DO NOT have relevant financial relationships
| Matthew Hall:No Answer
| Jane Newburger:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Royalties/Patent Beneficiary:UpToDate:Active (exists now)
; Other (please indicate in the box next to the company name):Daichii Sankyo (trial Steering Committee):Past (completed)
; Other (please indicate in the box next to the company name):BMS (Chair of DSMB for pediatric mavacamten trial):Active (exists now)
; Other (please indicate in the box next to the company name):Novartis (Chair, Independent EAC):Past (completed)
; Other (please indicate in the box next to the company name):BMS (Chair, Independent EAC):Active (exists now)
; Other (please indicate in the box next to the company name):Pfizer (Chair Independent EAC):Active (exists now)